LENZ Therapeutics, Inc.
HealthcareNASDAQ:LENZ · NASDAQ Global Select
+$0.27 today
Vol 0.28M · Avg 0.92M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$21.0M of revenue converted into -$109.0M of net income for the selected period. Gross margin is 75.8% and net margin is -1218.7%, showing how much revenue survives after costs and taxes. EPS is $-3.60, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.1M | $0 | $0 -100.0% | $15.0M | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $705.0K +1115.5% | $58.0K | $0 | $0 -100.0% | $734.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | $18.4M +31794.8% | -$58.0K | $0 -100.0% | $15.0M +2143.6% | -$734.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | 96.3% | — | — | 100.0% | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $18.7M -37.4% | $29.8M -49.9% | $59.5M +181.7% | $21.1M -44.3% | $37.9M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $90.9M +216.0% | $28.8M +122.4% | $12.9M +196.6% | $4.4M -80.0% | $21.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $109.5M +87.0% | $58.6M -19.2% | $72.4M +184.2% | $25.5M -57.3% | $59.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $287.0K +394.8% | $58.0K +286.7% | $15.0K +87.5% | $8.0K -98.9% | $734.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$81.3M -63.6% | -$49.7M +29.1% | -$70.1M -570.7% | -$10.5M +85.1% | -$70.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -426.1% | — | — | -69.7% | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$91.1M -55.5% | -$58.6M +19.1% | -$72.4M -590.9% | -$10.5M +82.7% | -$60.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -477.5% | — | — | -69.9% | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $9.8M +14.1% | $8.6M +290.7% | $2.2M | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $9.5M +7.6% | $8.8M +287.5% | $2.3M +11910.5% | $19.0K +100.2% | -$10.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$81.6M -64.0% | -$49.8M +29.1% | -$70.1M -570.4% | -$10.5M +85.2% | -$70.8M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -427.6% | — | — | -69.8% | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $502.0K +50100.0% | $1.0K +100.6% | -$179.0K -151.6% | $347.0K | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$82.1M -65.0% | -$49.8M +28.9% | -$70.0M -547.2% | -$10.8M +84.7% | -$70.8M | $4.9B | $4.8B | $4.7B |
| Net Margin | -430.3% | — | — | -72.1% | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -21.8% | -$2 +84.7% | -$15 -18.7% | -$13 -51.0% | -$9 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -21.8% | -$2 +84.7% | -$15 -18.7% | -$13 -51.0% | -$9 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $28.8M +35.4% | $21.3M +161.3% | $8.1M +3.9% | $7.8M -5.4% | $8.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $28.8M +35.4% | $21.3M +161.3% | $8.1M +3.9% | $7.8M -5.4% | $8.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
GH Research PLC
NASDAQ:GHRS
$1.45B
Savara Inc.
NASDAQ:SVRA
$1.08B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$969.20M
Arbutus Biopharma Corporation
NASDAQ:ABUS
$841.51M
Geron Corporation
NASDAQ:GERN
$737.75M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does LENZ generate?
LENZ Therapeutics, Inc. (LENZ) reported $19.09M of revenue in fiscal 2025.
Is LENZ profitable?
LENZ Therapeutics, Inc. (LENZ) reported -$82,127,000.00 of net income, with a net margin of -430.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.